Peter MacCallum Cancer Centre

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study (2026) Gaughan EM, Kim M, Mendez I, Rao AD, Wei M, So A, Zhong X, et al. Journal article Immune checkpoint inhibitor-associated myocarditis: A novel risk score (2026) Power JR, Dolladille C, Ozbay B, Procureur A, Ederhy S, Palaskas NL, Lehmann LH, et al. Journal article Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma (2026) Weeda YA, Salgado R, van Herpe F, Sur D, Vieth M, Loi S, Tafti AP, et al. Journal article, Review article Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC (2026) Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, et al. Journal article Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer (2026) Billaud A, Figlioli G, Mooser C, Casamassima I, Azzoni V, Srivatsa J, Colombo M, et al. Journal article Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy (2026) Filippi AR, Bar J, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, et al. Journal article Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival (2025) Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching P, Bardia A, Chia S, et al. Journal article Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial (2025) Fasching P, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, et al. Journal article Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis (2025) Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, Köbel M, et al. Journal article Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial (2025) Fasching P, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, et al. Journal article